Apellis Pharmaceuticals Inc EBITDA margin
¿Qué es el EBITDA margin de Apellis Pharmaceuticals Inc?
El EBITDA margin de Apellis Pharmaceuticals Inc es -44,492.23%
¿Cuál es la definición de EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin de compañías en Sector Health Care en NASDAQ en comparadas con Apellis Pharmaceuticals Inc
¿Qué hace Apellis Pharmaceuticals Inc?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Empresas con ebitda margin similar a Apellis Pharmaceuticals Inc
- Walkabout Resources tiene EBITDA margin de -47,688.31%
- Blue Star Helium tiene EBITDA margin de -47,121.89%
- Mont Royal Resources tiene EBITDA margin de -45,543.49%
- Checkpoint Therapeutics Inc tiene EBITDA margin de -45,501.28%
- Metallica Minerals tiene EBITDA margin de -45,139.43%
- Zeus Resources tiene EBITDA margin de -44,666.24%
- Apellis Pharmaceuticals Inc tiene EBITDA margin de -44,492.23%
- Nuveen NASDAQ 100 Dynamic Overwrite Fund tiene EBITDA margin de -44,294.34%
- Leonovus tiene EBITDA margin de -44,280.00%
- Lakes Oil NL tiene EBITDA margin de -43,029.19%
- Aimmune Therapeutics Inc tiene EBITDA margin de -42,733.57%
- Woomera Mining tiene EBITDA margin de -42,253.84%
- Amarillo Biosciences tiene EBITDA margin de -40,922.42%